From: Study on molecular expression of long non-coding RNA Glypican3 in hepatocellular cancer patients
Variable | HCC group I, n = 70 | Cirrhosis group II, n = 44 | Control group III, n = 30 | P1 value | P2 value | P3 value |
---|---|---|---|---|---|---|
Sex | ||||||
Females: n (%) Males: n (%) | 10 (14.3%) 60 (85.7%)a,b | 25 (56.8%) 19 (43.2%) | 11 (36%) 19 (64%) | 0.1 | < 0.001 | 0.037 |
Age (years) | 57.5 ± 6.7a,b | 42 ± 9.8 | 39.6 ± 10 | 0.5 | < 0.001 | < 0.001 |
T-bilirubin (mg/dl) | 1.36 ± 0.89a,b | 0.8 ± 0.34 | 0.83 ± 0.21 | 0.9 | < 0.001 | 0.009 |
AST (U/L) | 68.7 ± 35.5a | 57.6 ± 37a | 30.2 ± 6.1 | 0.008 | 0.2 | < 0.001 |
ALT (U/L) | 55 ± 29.9a | 61 ± 32.7a | 24.5 ± 7.4 | < 0.001 | 0.5 | < 0.001 |
Albumin (g/dl) | 3.3 ± 0.6a,b | 4.3 ± 0.76 | 4.27 ± 0.6 | 0.9 | < 0.001 | < 0.001 |
PC (%) | 74 ± 11a,b | 86 ± 10 | 87 ± 8.6 | 0.9 | < 0.001 | < 0.001 |
Platelets × 103/m3 | 132.8 ± 63.9a,b | 228 ± 69a | 279.6 ± 88 | 0.019 | < 0.001 | < 0.001 |
AFP (ng/ml) | 109 ± 40a,b | 10 ± 4 | 5.13 ± 2.9 | 0.009 | 0.001 | 0.9 |
GPC3 (ng/ml) | 6.3 ± 2.26a,b | 3.9 ± 0.8 | 3.76 ± 2.06 | < 0.001 | < 0.001 | 0.9 |
lncRNA AF085935 | 1.6 ± 0.8a,b | 0.95 ± 0.5 | 0.68 ± 0.2 | < 0.001 | < 0.001 | 0.29 |
Child–Pugh score of the HCC group | ||||||
A | Number of patients | % | ||||
25 | 35.7% | |||||
B | 12 | 17% | ||||
C | 33 | 47.3% | ||||
Imaging data of the HCC group | ||||||
No. of FL | Number of patients | % | ||||
1 | 41 | 58.5% | ||||
2 | 12 | 17% | ||||
Multiple | 17 | 24.5% | ||||
Site of FL | Right lobe | 55 | 78.5% | |||
Left lobe | 5 | 7.0% | ||||
Both lobes | 10 | 15.5% | ||||
Vascular invasion | Yes | 50 | 71.4% | |||
No | 20 | 28.6% | ||||
Abdominal LNs | yes | 45 | 64.0% | |||
no | 25 | 36.0% |